
TMV provides daily inverse (-3x) exposure to the ICE U.S. Treasury 20+ Year Bond Index. Using a combination of swaps and futures, TMV gives investors -3x exposure to daily moves in T-bonds with more than 20 years left to maturity. The daily reset means investors shouldn't expect the leverage factor to hold constant over investment horizons greater than one day. In short, the fund is a valid option for tactical positioning/hedging against rising interest rates, but it's important to keep in mind that the -3x leverage results in greater impact from the effects of compounding. As a levered…
Is TMV's expense ratio expensive, average, or a steal for its category?
Pro reveals the verdict on a 5-tier spectrum calibrated against ICI 2025 industry averages, with strategy-aware bands so the comparison is meaningful.

The Direxion Daily 20+ Year Treasury Bear 3X ETF offers -3X daily leverage on long-term Treasuries, making it a popular trading and hedging instrument. TMV's long-term drift is historically positive, benefiting from trending rate environments, but it can suffer decay during sideways markets due to beta-slippage. Since January 2022, TMV has gained 230.8% as rates surged, demonstrating its effectiveness as an interest rate hedge for fixed-income portfolios.

Rising oil prices, inflation fears and higher Treasury yields are creating a favorable backdrop for inverse Treasury ETFs.

Direxion Daily 20+ Year Treasury Bear 3x Shares (NYSEARCA:TMV - Get Free Report) passed above its two hundred day moving average during trading on Tuesday. The stock has a two hundred day moving average of $37.90 and traded as high as $42.80. Direxion Daily 20+ Year Treasury Bear 3x Shares shares last traded at

Treasury yields climbed as Middle East tensions linger. These inverse Treasury ETFs could benefit if inflation and bond yields keep rising.

SAN FRANCISCO--(BUSINESS WIRE)---- $TMV #AI--Weave Bio, a leader in AI-native regulatory automation for drug development, today announced the expansion of its Strategic Advisory Board (SAB) with the appointment of two former U.S. Food and Drug Administration leaders, Tala Fakhouri, Ph.D., M.P.H. chief AI and regulatory strategy officer at Parexel, and Sean Khozin, M.D., M.P.H., chief executive officer of the CEO Roundtable on Cancer and Project Data Sphere. Their appointments give the company firsthand insi.